Dallas, Texas 01/02/2014 (FINANCIALSTRENDS) – Novavax, Inc. (NASDAQ:NVAX) continues to gain ground, based on the success of its Respiratory Syncytial Virus Fusion Vaccine. This is in direct competition with MedImmunes’ Synagis, which currently enjoys much market segment growth, with sales approximating $1 billion in 2012.
Respiratory Syncytial Virus Fusion Vaccine is one of the most common of the seasonal viruses which spread very quickly and is typical of the common cold, with running noses, sneezing as well as coughing along with fever. Though, regarded as common, this virus does cause great suffering in infants, leading to lung diseases.
Novavax, Inc. (NASDAQ:NVAX) in September 2012, showed that the its Respiratory Syncytial Virus Fusion Vaccine was effective in the first Phase of trails on 220 adults, aged above 60 years and in good health. This vaccine was administered along with flu vaccine. The vaccine was found to cause no affects, besides increasing the antibodies which would lead to further protection, from the quick spreading virus.
Novavax, Inc. (NASDAQ:NVAX) has received strong backing by analysts because of the strong efficacy of its infection preventing vaccines for one of the most common and high incidence infections. Further, the preventive potential the vaccine holds in infant care, neonatal stages and in pregnant women does bolster higher valuation of the company. The vaccine in clinical trials protected senior citizens from succumbing to RSV when taken with flu shots.
Indicative Clinical data
Additionally, clinical data too indicates the efficiency of this drug, as reported in The New England Journal of Medicine. The study had used VLP A(H7N9) vaccine candidate, recording ‘in-line findings’ showing that the antibodies varied between 81% and 97% in those who were administered this vaccine.
Novavax, Inc. (NASDAQ:NVAX) RSV can prove to be pandemic in its use and see great growth, as news of the vaccine being released as a combination drug in US and Europe hits the headlines, with the expectation that RSV-F will notch $ 1 billion in sales the next half decade.